UBS Group
LUNG icon

UBS Group’s Pulmonx LUNG Stock Holding History

UBS Group’s Portfolio LUNG Stock Details LUNG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265K Sell
204,053
-5,648
-3% -$7.78K ﹤0.01% 6635
2026
Q1 		$271K Buy
209,701
+38,105
+22% +$63K ﹤0.01% 6462
2025
Q4 		$379K Buy
171,596
+90,304
+111% +$170K ﹤0.01% 6242
2025
Q3 		$132K Sell
81,292
-194,603
-71% -$407K ﹤0.01% 6938
2025
Q2 		$715K Buy
275,895
+192,833
+232% +$761K ﹤0.01% 5721
2025
Q1 		$559K Sell
83,062
-118,776
-59% -$841K ﹤0.01% 5760
2024
Q4 		$1.37M Buy
201,838
+180,665
+853% +$1.19M ﹤0.01% 5066
2024
Q3 		$176K Sell
21,173
-1,462
-6% -$10.6K ﹤0.01% 5969
2024
Q2 		$144K Sell
22,635
-24,705
-52% -$190K ﹤0.01% 5902
2024
Q1 		$439K Buy
47,340
+13,665
+41% +$160K ﹤0.01% 5300
2023
Q4 		$429K Buy
33,675
+9,624
+40% +$100K ﹤0.01% 5220
2023
Q3 		$248K Sell
24,051
-2,226
-8% -$25.8K ﹤0.01% 5208
2023
Q2 		$344K Sell
26,277
-1,498
-5% -$18.3K ﹤0.01% 5118
2023
Q1 		$311K Buy
27,775
+14,986
+117% +$148K ﹤0.01% 5055
2022
Q4 		$108K Sell
12,789
-391
-3% -$3.72K ﹤0.01% 6031
2022
Q3 		$220K Buy
13,180
+4,685
+55% +$86.3K ﹤0.01% 5007
2022
Q2 		$125K Sell
8,495
-4,538
-35% -$93.5K ﹤0.01% 5254
2022
Q1 		$324K Sell
13,033
-2,142
-14% -$55.3K ﹤0.01% 5007
2021
Q4 		$486K Buy
15,175
+11,895
+363% +$434K ﹤0.01% 5009
2021
Q3 		$118K Buy
3,280
+3,000
+1,071% +$118K ﹤0.01% 5712
2021
Q2 		$12K Sell
280
-4,254
-94% -$185K ﹤0.01% 7889
2021
Q1 		$207K Buy
4,534
+2,455
+118% +$141K ﹤0.01% 5461
2020
Q4 		$143K Buy
+2,079
New +$102K ﹤0.01% 5462

Other funds holding LUNG

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

UBS Group's LUNG Position: Q2 2026 in Review

UBS Group reduced its Pulmonx (LUNG) stake by 2.7% in Q2 2026, selling an estimated $7.78K and leaving 204,053 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #6635.

UBS Group first reported a position in LUNG in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.37M in Q4 2024. 108 funds tracked by Wall St. Rank hold LUNG as of Q2 2026.

  • UBS Group held 204,053 shares of Pulmonx worth $265K as of Q2 2026.
  • UBS Group sold 5,648 Pulmonx shares in Q2 2026, an estimated $7.78K.
  • Pulmonx made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6635 holding.
  • UBS Group first reported a position in Pulmonx in Q4 2020 and has held it in 23 quarters since.
  • UBS Group's Pulmonx position peaked at $1.37M in Q4 2024.
  • 108 funds tracked by Wall St. Rank held Pulmonx as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.